DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for rhinitis — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRhinitis maps to a 36-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rhinitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAR related orphan receptor A (RORA) — RORA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3beta,4alpha,5beta,14betadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4S15 · 1.897 Å · ligand (3beta,4alpha,5beta,14beta)-3-hydroxy-4-methylcholesta-8,24-diene-4-carboxylic acid (4D8). Experimental structure, not a prediction.
What the evidence adds up to
Allergic rhinitis affects millions of people worldwide, but many aspects of its pathology and treatment remain unclear and warrant further investigation, according to a 2019 review. The same review notes that recent studies have covered the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics, but does not report any concrete survival or response rates from those studies. A 2011 update states that uncontrolled allergic rhinitis has been associated with impairments in quality of life and decreased economic productivity, and that first-line therapy includes an intranasal steroid, with other options including oral or intranasal antihistamines, decongestants, leukotriene receptor antagonists, mast cell stabilisers, or anticholinergic agents. Immunotherapy is described as an effective treatment option for refractory disease, but again no numerical efficacy data are given.
A 2016 article on acute rhinitis provides practical guidance on the topical drug Otrivin but does not report any trial results, sample sizes, or response rates. A 2023 scoping systematic review of ongoing clinical trials of experimental treatments for rhinitis states that current treatments, including antihistamines, intranasal corticosteroids, and immunotherapy, have limitations such as side effects and incomplete symptom relief. That review aims to identify and map ongoing trials and categorise emerging therapies, but it does not present any completed trial outcomes or numerical evidence of efficacy for any experimental treatment.
No abstract provides concrete numbers for survival, response rates, or sample sizes for any drug treatment for rhinitis. The evidence base is limited to narrative reviews and a protocol for a scoping review of ongoing trials. What is still missing are completed, adequately powered randomised controlled trials that report objective outcomes, sufficient funding to conduct such trials, and better patient stratification to identify which subgroups, if any, might benefit from emerging therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Allergy · 2019 · 184 citations · open access
Recent developments and highlights in allergic rhinitis
AbstractAllergic rhinitis (AR) is a disease with high prevalence all over the world and therefore needs to be thoroughly investigated and treated accordingly. The mechanisms underlying the pathology and treatment of AR have been widely studied, but many aspects remain unclear and warrant further investigations. This review presents an overview of recently published papers highlighting the risk factors, mechanisms, and treatment of AR. Additionally, recent studies discussing the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics in AR are also covered.
Meditsinskiy sovet = Medical Council · 2016 · 7 citations · open access
APPROACHES TO ACUTE RHINITIS THERAPY
AbstractThe article deals with modern ideas about etiology and pathogenesis of acute rhinitis, various therapeutic options are considered, the most frequently used pharmaceuticals are characterized. Practical guidance on application of topic drugs (Otrivin) for acute rhinitis therapy is provided.
Open Science Framework · 2023 · 0 citations · open access
Emerging therapies for rhinitis: A scoping systematic review of ongoing clinical trials of experimental treatments
AbstractRhinitis is a common condition affecting millions of people worldwide. Current treatments, including antihistamines, intranasal corticosteroids, and immunotherapy, have limitations, such as side effects and incomplete symptom relief. New treatments are being developed to address these limitations, and a scoping review of ongoing clinical trials can provide an overview of emerging therapies for rhinitis. The objective of this scoping review is to identify and map ongoing clinical trials of experimental treatments for rhinitis, categorize these treatments, and provide a comprehensive overview of the current landscape of emerging therapies.
Clinical Medicine Insights Therapeutics · 2011 · 0 citations · open access
Update on Clinical Options for the Management of Allergic Rhinitis
AbstractAllergic rhinitis is a common, chronic medical condition affecting millions of people worldwide. Uncontrolled disease has been associated with impairments in quality of life and decreased economic productivity. Proper identification and control of relevant co-morbid conditions is essential for optimal rhinitis control. Management of allergic rhinitis includes identification of relevant allergens, education on avoidance measures, medications and immunotherapy. First-line therapy includes the use on an intranasal steroid. Other treatment options include oral or intranasal antihistamines, decongestants, leukotriene receptor antagonists, mast cell stabilizers or anticholinergic agents. Immunotherapy is an effective treatment option for refractory disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
